SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals informs about media release

19 Mar 2026 Evaluate

Glenmark Pharmaceuticals has informed that the company has received final approval by the United States Food & Drug Administration (U.S. FDA) for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC). Glenmark’s Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC) has been determined by the FDA to be bioequivalent1 to the reference listed drug, Flonase®2 Allergy Relief Nasal Spray, 50 mcg per spray, of Haleon US Holding LLC [NDA – 205434]; and will be distributed in the U.S. by Glenmark Therapeutics Inc., USA. The company has attached media release in this regard.

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharma Share Price

2229.50 -18.40 (-0.82%)
20-Apr-2026 15:28 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1666.00
Dr. Reddys Lab 1226.10
Cipla 1228.55
Zydus Lifesciences 932.60
Lupin 2326.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×